- Home
- LPTX vs ALOT Comparison
LPTX vs ALOT Comparison
Compare LPTX & ALOT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- LPTX
- ALOT
- Stock Information
- Founded
- LPTX 2011
- ALOT 1969
- Country
- LPTX United States
- ALOT United States
- Employees
- LPTX N/A
- ALOT N/A
- Industry
- LPTX Biotechnology: Biological Products (No Diagnostic Substances)
- ALOT Computer peripheral equipment
- Sector
- LPTX Health Care
- ALOT Technology
- Exchange
- LPTX Nasdaq
- ALOT Nasdaq
- Market Cap
- LPTX 119.6M
- ALOT 114.8M
- IPO Year
- LPTX N/A
- ALOT N/A
- Fundamental
- Price
- LPTX $2.55
- ALOT $12.06
- Analyst Decision
- LPTX Strong Buy
- ALOT
- Analyst Count
- LPTX 3
- ALOT 0
- Target Price
- LPTX $7.50
- ALOT N/A
- AVG Volume (30 Days)
- LPTX 335.2K
- ALOT 13.4K
- Earning Date
- LPTX 11-13-2024
- ALOT 12-12-2024
- Dividend Yield
- LPTX N/A
- ALOT N/A
- EPS Growth
- LPTX N/A
- ALOT 12.82
- EPS
- LPTX N/A
- ALOT 0.51
- Revenue
- LPTX N/A
- ALOT $153,515,000.00
- Revenue This Year
- LPTX N/A
- ALOT N/A
- Revenue Next Year
- LPTX N/A
- ALOT N/A
- P/E Ratio
- LPTX N/A
- ALOT $23.82
- Revenue Growth
- LPTX N/A
- ALOT 3.48
- 52 Week Low
- LPTX $1.68
- ALOT $11.00
- 52 Week High
- LPTX $4.79
- ALOT $18.83
- Technical
- Relative Strength Index (RSI)
- LPTX 37.35
- ALOT 40.56
- Support Level
- LPTX $2.88
- ALOT $11.00
- Resistance Level
- LPTX $3.27
- ALOT $13.38
- Average True Range (ATR)
- LPTX 0.28
- ALOT 0.55
- MACD
- LPTX -0.06
- ALOT 0.05
- Stochastic Oscillator
- LPTX 12.71
- ALOT 44.54
About LPTX Leap Therapeutics Inc.
Leap Therapeutics Inc is in developing targeted antibody therapies for cancer treatment, focusing on inhibiting tumor-promoting pathways, targeting cancer-specific cell surface molecules, and activating the immune system against cancer cells. The company's lead program, DKN-01, targets Dickkopf-related protein 1 (DKK1) and is in clinical trials for esophagogastric, gynecologic, and colorectal cancers. Their second program, FL-301, targets Claudin18.2-expressing cells. Additionally, the company has two preclinical antibody programs, FL-302 and FL-501, aimed at developing transformative cancer treatments. Operating as a single segment, the company's sole focus is on developing innovative drugs to address unmet needs in cancer therapy. .
About ALOT AstroNova Inc.
AstroNova Inc designs, develops, manufactures, and distributes a broad range of specialty printers and data acquisition and analysis systems, including both hardware and software, which incorporate technologies to acquire, store, analyze, and present data in multiple formats sold under the QuickLabel, TrojanLabel and GetLabels brand names. Its target markets for hardware and software products include aerospace, apparel, automotive, avionics, chemicals, computer peripherals, communications, distribution, food and beverage, general manufacturing, packaging, and transportation. It has two segments, Product Identification (PI) and Test & Measurement (T&M). It generates the majority of its revenue from the PI segment that includes specialty printing systems and related supplies.